top of page

Create Your First Project

Start adding your projects to your portfolio. Click on "Manage Projects" to get started

Hotels-Models14015 2_edit_new 2.jpg

Zymeworks’ lead product candidate, zanidatamab, is a HER2-targeted bispecific antibody developed using Zymeworks proprietary Azymetric™ platform. Zanidatamab is currently being evaluated as a best-in-class treatment for patients with HER2-expressing cancers, including biliary tract, gastroesophageal adenocarcinomas, breast, and other tumor types.

Entry Price: $7.47

Date

November 2022

Zymeworks

bottom of page